Chinese

advanced search

News & Events

Home News & Events Content

Yttrium-90 [90Y] microsphere selective internal radiation therapy for liver cancer is successfully implemented

Updated: May 9, 2022
From: Publicity Department
Edited by: Liu Huiting
Hits:

On the afternoon of May 6, the MDT team of radionuclide therapy for liver cancer from Department of Hepatobiliary Surgery and Department of Nuclear Medicine of the First Affiliated Hospital of Xi 'an Jiaotong University (XJTU) successfully carried out one of the first batch in China and the first case of Yttrium-90 [90Y] microsphere selective internal radiation therapy (90Y-SIRT) in western China.

Patients with unresectable liver cancer mainly receive interventional therapy. With the introduction of SIR-Spheres® Yttrium [90Y] microsphere injection (GRANDPHARMA (China) Co., Ltd.),90Y-SIRT provides a novel strategy for prolonging the survival of patients with unresectable liver cancer.

In liver cancer,90Y local irradiation can increase the irradiation dose to the cancer lesions, and achieve a therapeutic effect equivalent to surgical resection of cancer lesions or involved liver segments. Based on the ideal physical and chemical properties of 90Y nuclide, SIR-Spheres Yttrium 90 [90Y] microsphere injection was approved by National Medical Products Administration (NMPA) in 2022, becoming the first therapeutic radioactive drug in China.

A 59-year-old patient, surnamed Shi, was admitted to our hospital two months ago due to "space-occupying lesions of the liver during physical examination", which was initially diagnosed as liver malignancy. Professor Liu Qingguang's team from Department of Hepatobiliary Surgery considered that the patient was old, the liver tumor was large and the tumor location was not ideal. Hence, it was not suitable to perform surgical resection. Moreover, the patient was unwilling to receive systemic chemotherapy. Our hospital set up an MDT team for radionuclide therapy of liver cancer, consisting of Department of Hepatobiliary Surgery, Department of Nuclear Medicine, Interventional Surgery Center and relevant experts,to determine a comprehensive and explicit interventional surgical plan using 90Y microspheres. Director Wang Yuan, a radiation safety supervision expert, from Department of Ecology and Environment of Shaanxi Province was invited to join hands with Guo Jianxin, Director of Radiation Management Office of our hospital, to monitor and evaluate the radiation safety throughout the whole treatment process, providing technical guidance for safe implementation of radionuclide diagnosis and treatment in our hospital.

At the noon on May 6, an expert team, including Professor Lyu Yi, Vice President of XJTU and President of our hospital, conducted another round of consultation, evaluation on the patient and offered guidance on the treatment. The MDT team of radionuclide therapy for liver cancer from Department of Hepatobiliary Surgery and Department of Nuclear Medicine successfully carried out 90Y-SIRT.

The success of 90Y-SIRT for liver cancer indicates that our hospital possesses another critical and effective  "weapon" in comprehensive treatment of liver malignancy. Successful implementation of 90Y-SIRT will lay a solid foundation for our hospital in the field of precise treatment and integrated radionuclide diagnosis and treatment of tumors.

Previous:Mapping genomic loci implicates genes and synaptic biology in ​schizophrenia
Next:Mu Jianjun's team makes significant progress in the field of obesity and albuminuria

Copyright (c) 2011, First Affiliated Hospital of Xi 'an Jiaotong University Shaanxi ICP for 12009712-3